Shares of Avacta Group Plc (OTCMKTS:AVCTF – Get Free Report) rose 2.1% during trading on Friday . The stock traded as high as $0.9550 and last traded at $0.9550. 3,000 shares were traded during trading, a decline of 88% from the average daily volume of 24,927 shares. The stock had previously closed at $0.9355.
Avacta Group Price Performance
The firm has a 50-day moving average of $0.94 and a two-hundred day moving average of $0.95.
About Avacta Group
Avacta Group plc is a UK-based biotechnology company specializing in the discovery, development and commercialization of Affimer® biotherapeutics and diagnostic reagents. The company’s proprietary Affimer platform uses small, engineered protein scaffolds that can be tailored to bind specifically to target molecules, offering an alternative to traditional antibodies. Avacta operates two core divisions: Avacta Therapeutics, which focuses on novel treatments in oncology and immune-related diseases, and Avacta Analytical, which develops reagents and point-of-care diagnostic tests.
In its diagnostics business, Avacta has applied the Affimer technology to lateral flow assays, most notably for rapid detection of viral pathogens such as SARS-CoV-2.
Further Reading
- Five stocks we like better than Avacta Group
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
